Abstract

Background: Drug-drug interactions (DDIs) are an important cause of adverse drug reactions (ADRs). In literature most of studies focus only on potential DDIs, while detailed data on serious ADRs associated with DDIs are limited. Our aim is to identify and characterize serious ADRs caused by DDIs using a spontaneous reporting database. Methods: All serious ADR reports, not related to vaccines and with a “definite”, “probable” or “possible” causality assessment, inserted into the National Pharmacovigilance database from Veneto Region (January 1, 2015 to May 31, 2020) were analyzed. A list of drug pairs was created by selecting the reports containing at least two suspected or concomitant drugs. We verified which drug pairs potentially interacted according to the online version of DRUGDEX® system. For each potential DDI we controlled whether the ADR description in the report corresponded to the interaction effect as described in Micromedex. A detailed characterization of all serious reports containing an occurring DDI was performed. Results: In the study period a total of 31,604 reports of suspected ADRs from the Veneto Region were identified, of which 2,195 serious reports (6.9% of all ADR reports) containing at least two suspected or concomitant drugs were analyzed. We identified 1,208 ADR reports with at least one potential DDI (55.0% of 2,195) and 381 reports (17.4% of 2,195 reports) with an occurring ADR associated with a DDI. The median age of patients and the number of contraindicated or major DDIs were significantly higher in reports with an occurring DDI. Warfarin was the most frequently reported interacting drug and the most common ADRs were gastrointestinal or cerebral hemorrhagic events. The proton pump inhibitors/warfarin, followed by platelet aggregation inhibitors/warfarin were the drug-drug combinations most frequently involved in ADRs caused by DDIs. The highest proportion of fatal reports was observed with platelet aggregation inhibitors/warfarin and antidepressants/warfarin. Conclusion: Our findings showed that about one-third of patients exposed to a potential DDI actually experienced a serious ADR. Furthermore, our study confirms that a spontaneous reporting database could be a valuable resource for identifying and characterizing ADRs caused by DDIs and the drugs leading to serious ADRs and deaths.

Highlights

  • The increasing multimorbidity and the rising numbers of guidelines focusing on how to treat specific medical conditions have led to widespread polypharmacy, especially in the elderly

  • This was the starting point for a previous article in which we described the percentage and characteristics of patients exposed to a potential drug-drug interactions (DDIs) who experienced a related Adverse drug reactions (ADRs) by analyzing an Italian spontaneous reporting database (Leone et al, 2010), though without focusing on the seriousness of DDI

  • Some authors quantified the importance of drug-drug interactions in the occurrence of ADRs in a pharmacovigilance database, focusing in particular on serious events related to DDIs (Mirosevic Skvrce et al, 2011; Montastruc et al, 2012)

Read more

Summary

Introduction

The increasing multimorbidity and the rising numbers of guidelines focusing on how to treat specific medical conditions have led to widespread polypharmacy, especially in the elderly. A spontaneous reporting database could be an appropriate and valid source to identify, characterize and to quantify the suspected ADRs resulting from DDIs (Van Puijenbroek et al, 2000; Thakrar et al, 2007; Hult et al, 2020). This was the starting point for a previous article in which we described the percentage and characteristics of patients exposed to a potential DDI who experienced a related ADR by analyzing an Italian spontaneous reporting database (Leone et al, 2010), though without focusing on the seriousness of DDI. Our aim is to identify and characterize serious ADRs caused by DDIs using a spontaneous reporting database

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call